Citations

Clear

136 citation(s) found for "Sherif, A".

Comparison of neuropsychological side effects between contemporary radiofrequency ablative neurosurgery for psychiatric disorders and conventional neurosurgical procedures: systematic review and meta-analysis
Vilela-Filho, Osvaldo , Bannach, Matheus A., Lino-Filho, Adriano M. , Nuttin, Bart , Hariz, Marwan , Schulder, Michael , Greenberg, Benjamin David, Cosgrove, Rees, Oliveira-Souza, Ricardo de, Horn, Andreas, Sheth, Sameer A, Kubu, Cynthia S. , Salem, Sherif, Zaccariotti, Alice Jardim, Tavares, Naraiana O, Damasceno, Benito Pereira, Lozano, Andres M, Visser-Vandewalle, Veerle, Kühn, JP, Slavin, K. V., Lopes, A. Dwight, Vattimo, Edoardo FQ, Coyne, Terry, Akram, Harith, Toda, Hiroki , Halpern, Casey H. , Coenen, Volker A., Gorgulho, Alessandra, Andrade, Pablo, Wu, Hemmings , Sun, Bomin, Belmonte-De-Abreu, Paulo, Cosyns, Paul, McLaughlin, Nicole , Giordano, Prof. J., Berk, Michael, Chabardes, Stephan, Abbadi, Najia E, Salles, Antonio Afonso Ferreira De, Enslin, Nico, Sousa, Marcelo Basso de, Oliveira, José Oswaldo, Labruna, Rodrigo, Reis, Antonio Marcos dos , Jiménez-Ponce, Fiacro , Ferragut, Maria Alice, Régis, Jean, Lipsman, Nir , Rezai, Ali R. , Schuurman, Rick, Martínez-Álvarez, Roberto, Broggi, Giovanni, Huys, Daniel, Bervoets, Chris , Oliveira, P. A., Ragazzo, Paulo C., Lazaro-Munoz, Gabriel, Polosan, Mircea , Naesström, Matilda, Ribeiro, Telma MC, Lee, Kendall H, Hodaie, Mojgan , Sitnikov, Andrey, Yilmaz, Atilla, Almahariq, F., Rios, Adriana L Lopez, Gonçalves-Ferreira, António, Lozano, Andrés M. , Huys, Daniel , Enslin, Nico , Nuttin, Bart , Hariz, Marwan , Sheth, Sameer A , Damasceno, Benito Pereira , Kuhn, Jens , Slavin, Konstantin V. , Doshi, Paresh , Toda, Hiroki , Andrade, Pablo , Zrinzo, Ludvic , Chabardes, Stephan , Chang, Jin Woo , Polosan, Mircea , Hodaie, Mojgan , Almahariq, Fadi , Nico Enslin, Johannes M , Hamani, Clement , Greenberg, Benjamin D. , Oliveira‐Souza, Ricardo de , Sheth, Sameer A. , Zaccariotti, Alice Jardim , Tavares, Naraiana de Oliveira , Mayberg, Helen S. , Visser-Vandewalle, Veerle E. R. M. , Falkai, Peter , Lopes, Antonio C, Vattimo, Edoardo Filippo de Queiroz , Akram, Harith , Blomstedt, Patric C. , Quevedo, João , Belmonte-de-Abreu, Paulo Silva , Alkhani, Ahmed M. , Berk, Michael , Yatham, Lakshmi N. , Abbadi, Najia El , Salles, Antonio A. F. De, Chang, Jin Woo , Régis, Jean , Torres, Cristina V. , Taira, Takaomi , Barcia, Juan Antonio , Schuurman, Rick , Dougherty, Darin Dean , Giacobbe, Peter , Lázaro‐Muñoz, Gabriel , Naesström, Matilda , Johansson, Viktoria , Schlaepfer, Thomas Eduard , Neimat, Joseph S. , Sitnikov, A., Yilmaz, Atilla, Almahariq, Fadi, Ríos, Adriana Lucia López , Gonçalves-Ferreira, António JC.

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | April 7, 2026 | Volume: 97 | Issue: 6 | Pages: 532-541

10.1136/jnnp-2025-337800 | PMID 41946555 Get It

Background Psychiatric disorders are increasingly contributing to global disability. Despite advances in conservative management, the prevalence of treatment-resistant cases remains high. Meanwhile, neurosurgery for psychiatric disorders (NPD) remains underused, largely due to strict regulations and historical concerns, particularly those related to neuropsychological side effects (NPSE). Objective To address this issue, we conducted a systematic review with meta-analysis to compare NPSE associated with radiofrequency ablative NPD to those observed in neuro-oncological, neurovascular and epilepsy surgeries. Methods PubMed, Embase and LILACS databases were searched in April 2024 for articles published in English/Spanish from 1990 to 2022, following Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Results A total of 48 articles with 2678 participants were included. The frequency of transient and permanent NPSE in the NPD group ranged from 0.94% to 11.50% and 0.94% to 2.03%, respectively, comparable to the other surgical groups (epilepsy: 0.31–11.70%; vascular: 0.52–22.90%; oncology: 0.94–17.60% for transient NPSE; epilepsy: 0.31–12%; vascular: 0.40–1.96% and oncology: 0.84–1.48% for permanent NPSE). Regarding permanent NPSE, arguably the most critical consideration, the NPD group showed better outcomes in memory, language and social cognition than the epilepsy group, but worse outcomes in executive and perceptual-motor functions. Compared with the vascular group, the NPD group had better executive function but worse complex attention. Finally, the NPD group had fewer permanent deficits than the oncology group in executive function, complex attention and perceptual-motor domains, although language performance was lower. Conclusions Contemporary NPD apparently carries a similar risk of NPSE as other conventional neurosurgical procedures, challenging misconceptions and this unjustified barrier to its broader use.
Impact of SGLT2 Inhibitors on Kidney Function Among People With HIV: A US Prospective Multisite Study
Haidar, Lara, Crane, Heidi M, Nance, Robin M., Bamford, Laura, Burkholder, Greer, Cachay, Edward, Christopoulos, Katerina, Commanday, Alexander, Aboulatta, Laila, Delaney, J A C, Fahey, Carolyn, Heath, S. S., Kalayjian, Robert, Kitahata, Mari M, Kyle, Ryan, Mayer, K., Moore, Richard D, Pettit, April C, Napravnik, Sonia, Saag, M. S., Willig, Amanda L., Whitney, Bridget M. , Kyle, Ryan P. , Eltonsy, Sherif , Haidar, Lara, Crane, Heidi M. , Nance, Robin M. , Doupe, Malcolm Bray , Leong, Christine , Burkholder, Greer , Cachay, Edward R. , Christopoulos, Katerina A. , Delaney, Joseph A. , Drumright, Lydia N. , Kalayjian, Robert C. , Kitahata, Mari M. , Kyle, Ryan P., Moore, Richard D. , Pettit, April Christine , Napravnik, Sonia , Ruderman, Stephanie A. , Willig, Amanda L

Mayo Clinic

JAIDS Journal of Acquired Immune Deficiency Syndromes | February 24, 2026 | Volume: 101 | Issue: 6 | Pages: 680-687

10.1097/qai.0000000000003854 | PMID 41733274 Get It

Background: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are nephroprotective but are associated with early eGFR decline, also termed “eGFR dip.” Despite elevated risk of kidney disease, this phenomenon is understudied among people with HIV (PWH). Methods: In a 1:1 propensity score–matched cohort study using data from 9 Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) sites, we compared new SGLT2i users with new users of other antihyperglycemic classes. We estimated adjusted hazard ratios (aHRs) for time to ≥10% and ≥30% eGFR decline using multivariable Cox proportional hazards models and analyzed eGFR change using multivariable linear mixed models. In addition, longer-term eGFR trends over 24 months were visualized using locally weighted scatterplot smoothing (LOWESS) curves. Results: Among 1554 eligible PWH, we obtained 295 matched pairs. Over 6 months, eGFR decline incidence of ≥10% and ≥30% was higher among users of SGLT2i versus other antihyperglycemic classes (58.2% vs. 37.4%; aHR: 1.79; 95% CI: 1.40%–2.28%; and 17.3% vs. 9.8%; aHR: 1.69; 95% CI: 1.05–2.73; respectively). The adjusted mean eGFR change at 6 months was −2.62 mL/min/1.73 m 2 for SGLT2i versus 0.05 mL/min/1.73 m 2 for other classes. Long-term eGFR trends revealed an expected initial decline after SGLT2i initiation, followed by stabilization and a slower subsequent decline compared with other classes. Conclusions: Acute eGFR dips were more common among PWH initiating SGLT2i relative to other antihyperglycemic classes, although overall declines were small, transient, and consistent with the general population. Further research is needed to explore the long-term effects of SGLT2i in PWH.
Impact of Clostridioides difficile Infection on Clinical Outcomes in Hospitalized Patients With Inflammatory Bowel Disease
Duggal, Shivangini , Khattar, Sakar, Batheja, Mashal, Zuckerman, Marc J. , Elhanafi, Sherif , Elhanafi, Sherif E, Kattamuri, Lakshmi Prasanna Vaishnavi

Mayo Clinic

Journal of Clinical Gastroenterology | December 31, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/mcg.0000000000002323 | PMID 41474633 Get It

Introduction: Clostridioides difficile infection (CDI) is a major complication in patients with inflammatory bowel disease (IBD), contributing to increased morbidity, mortality, and health care burden. This study aimed to evaluate national trends and clinical outcomes associated with CDI in hospitalized IBD patients in the United States. Methods: We conducted a retrospective cohort study using the National Inpatient Sample (NIS) from 2012 to 2021. Adult patients hospitalized with a primary or secondary diagnosis of IBD (Crohn’s disease or ulcerative colitis) were stratified into 2 groups by the status of CDI diagnosis (either primary or secondary diagnosis). Demographic characteristics, hospital outcomes, and complications were compared between CDI and non-CDI cohorts. Multivariable logistic regression was used to identify independent predictors of in-hospital mortality, septic shock, and venous thromboembolism (VTE). Results: Among 4,193,564 hospitalized IBD patients, 534,190 (12.7%) had CDI. CDI patients were older (mean: 68.8 vs 53.3 y, P < 0.001), with higher in-hospital mortality (3.6% vs 2.0%, P < 0.001), VTE (23.7% vs 6.2%, P < 0.001), septic shock (5.4% vs 4.0%, P < 0.001), and mechanical ventilation use (4.2% vs 2.8%, P < 0.001). Ulcerative colitis was more frequently associated with CDI than Crohn’s disease (30.3% vs 25.0%, P < 0.001) and independently predicted septic shock (OR: 1.09) and VTE (OR: 1.06) but was associated with lower mortality (OR: 0.81). Conclusion: The presence of CDI in hospitalized patients with IBD led to significantly worse outcomes. Ulcerative colitis is more commonly associated with CDI and increased risk of complications. These findings highlight the need for early detection, preventive strategies, and tailored management of CDI in the IBD population.
Rural-urban disparities in survival rates in adult Hodgkin lymphoma: A population-based study
Elhusseiny, Khaled , Chen, Xuan , Hajjar, Adnan Humam, Hassan, Ibrahim , Sharief, Nourin, Shah, Jay , Hebishy, Ahmed, Hassan, Ibrahim , Mahmoud, Alaa, Sherif, Nourin Ali , Mahadevia, Himil , Mahmoud, Alaa

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3625-3625

10.1182/blood-2025-3625 Get It

Abstract Introduction Hodgkin's lymphoma is known to have favorable survival outcomes; however, limited data exist regarding survival disparities between rural and urban populations. In this study, we aimed to investigate the differences in survival outcomes between the two populations. Methods Data for patients diagnosed with Hodgkin lymphoma (HL) between 2000 and 2015 were extracted from the Surveillance, Epidemiology, and End Results (SEER) database. Rurality was identified using the Rural-Urban Continuum Codes (RUCC). Patients aged ≥ 20 years with HL as the only primary malignancy were included. Individuals with unknown race or those diagnosed at autopsy were excluded. The Ann Arbor Staging system was utilized for HL staging at diagnosis. HL-specific survival was defined as the time from diagnosis to death attributable to HL and was censored at the time of death from other causes or at last follow-up. Meanwhile, overall survival (OS) was defined as the time from diagnosis to death from any cause and was censored if the patient was still alive. A Cox proportional hazards model was performed to analyze the predictors for 10-year overall and HL-specific mortality. All statistical analyses were conducted using RStudio (version 2024.12.0). Results Between 2000 and 2015, a total of 22,505 patients diagnosed with Hodgkin lymphoma (HL) were included in the analysis. Among them, 13,657 (61%) were aged between 20 and 44 years. Overall, 10,137 patients (47%) were female, 14,885 (66%) were White, 2,672 (12%) were Black, and 3,724 (17%) were Hispanic. The majority of patients resided in urban counties, while only 2,266 (10.1%) lived in rural areas. Among rural patients, 845 (37%) were diagnosed with stage II disease, followed by 475 (21%) with stage III at the time of diagnosis. Notably, both the 10-year overall survival (69.5%) and Hodgkin lymphoma–specific survival (79.7%) were significantly lower among rural patients compared with urban patients (75.3% and 83.5%, respectively; p &lt; 0.001). In the multivariable model for 10-year HL-specific survival, older age (&gt; 65 years) was associated with the highest risk of mortality (HR 10.32; 95% CI 9.42–11.32). Although survival improved over the study period, male patients remained at increased risk of mortality (HR 1.26; 95% CI 1.18–1.35). Urban residence, diagnosis in more recent years, early stage, female sex, White race, and married status were independently associated with improved overall survival (p &lt; 0.01). Conclusion In this population-based study, both the 10-year overall and HL-specific survival were consistently lower among rural vs. urban patients. Male sex, older age, and unmarried status were particularly associated with worse survival outcomes. Further research is warranted to identify possible strategies for improving healthcare access and reducing survival disparities among rural patients.
Outcomes of bispecific T-cell engagers in MM patients with central nervous system (CNS) involvement
Gaballa, Mahmoud, Feng, Lei, Afrough, Aimaz, Banerjee, Rahul, Davis, James, Borogovac, Azra, Zanwar, Saurabh, Julian, Kelley, Biran, Noa, Puglianini, Omar Alexis Castaneda, Mikkilineni, Lekha, Ferreri, Christopher, Herr, Megan, Shune, Leyla, Bhurtel, Evguenia, Dima, Danai, Pasvolsky, Oren, Green, Kimberly, Janakiram, Murali, Hassan, Hamza, Kalariya, Nilesh, Corraes, Andre, Fogel, Lindsay, Singhal, Ruchi, Grajales-Cruz, Ariel, Blue, Brandon, Haider, Asad, Sannareddy, Aishwarya, Seif, Sherif, Thomas, Sheeba, Rana, Masooma, Ye, J Christine, Richards, Tiffany, Hosoya, Hitomi, Atrash, Shebli, Anderson, Larry, Goldsmith, Scott, Sidana, Surbhi, Voorhees, Peter, Sborov, Douglas, Lin, Yi, Portuguese, Andrew, Hansen, Doris, Patel, Krina, Sidana, Surbhi , Hosoya, Hitomi , Davis, James A. , Sidana, Surbhi , Davis, James A , Hosoya, Hitomi , Sannareddy, Aishwarya , Gaballa, Mahmoud, Feng, Lei, Afrough, Aimaz, Banerjee, Rahul, Davis, James, Borogovac, Azra, Zanwar, Saurabh, Julian, Kelley, Biran, Noa, Puglianini, Omar Alexis Castaneda, Mikkilineni, Lekha, Ferreri, Christopher, Herr, Megan, Shune, Leyla, Bhurtel, Evguenia, Dima, Danai, Pasvolsky, Oren, Green, Kimberly, Janakiram, Murali, Hassan, Hamza, Kalariya, Nilesh, Corraes, Andre, Fogel, Lindsay, Singhal, Ruchi, Grajales-Cruz, Ariel, Blue, Brandon, Haider, Asad, Seif, Sherif, Thomas, Sheeba, Rana, Masooma, Ye, J Christine, Richards, Tiffany, Atrash, Shebli, Anderson, Larry, Goldsmith, Scott, Voorhees, Peter, Sborov, Douglas, Lin, Yi, Portuguese, Andrew, Hansen, Doris, Patel, Krina

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 824-824

10.1182/blood-2025-824 Get It

Abstract Background Patients (pts) with multiple myeloma and CNS involvement (CNS MM) have poor outcomes, and we recently showed that CAR-T has activity and is reasonable in this population (Gaballa et al., 2025). We sought to evaluate the safety and efficacy of Bispecific T-cell engagers (BsAbs) in CNS MM pts, with specific interest in evaluating ICANS. Methods We conducted a retrospective study of CNS MM pts treated with BsAbs via the MM immunotherapy consortium. Primary endpoints were toxicity rates, with a specific focus on ICANS. Secondary endpoints were systemic responses, CNS responses, and survival outcomes. CNS MM was defined as involvement of the brain parenchyma, spinal cord tissue, leptomeningeal disease, or CSF positivity. CNS response was determined based on CSF and imaging, as complete CNS response, partial CNS response, and non-response/progression. Results The study included 24 pts from 13 US institutions treated with teclistamab (33%), talquetamab (50%), elranatamab (17%), and were used as monotherapy in 83% while 17% received them in combination with either daratumumab or IMiDs. The median age was 64.5 (range 41-82), 50% female, 79% white, and 17% black. High-risk cytogenetics were identified in 39%, 4% had prior primary PCL, and 21% had secondary PCL (2 active within 30 days of BsAb initiation). All pts were triple-refractory, 33% were penta-refractory, and 39% had non-CNS EMD. Pts received a median of 5 prior lines of therapy (IQR 4-7), 71% prior transplant, and 21% prior CAR-T. Prior BCMA therapy was received in 83% of the talquetamab group and 17% of the BCMA BsAbs group (teclistamab and elranatamab). CNS disease was determined based on both imaging and CSF findings in 58%, imaging only in 33%, and CSF only in 8%. Site of CNS disease included 42% brain/cranial nerves, 13% spinal cord, or 46% with both. CNS disease was diagnosed prior to BsAb in 19 pts, with a median interval of 46 days (IQR 7-234), and 3 pts were identified within 2 weeks after BsAb initiation. Two pts identified at days 68 and 121 were included in the safety evaluation but excluded from the efficacy assessments. One pt received teclistamab and intrathecal chemotherapy (IT chemo) as a bridge to CAR-T and achieved a complete CNS response before CAR-T. CNS-directed therapy consisted of: 30% radiotherapy (RT), 30% IT chemo, 13% RT + IT chemo, 9% RT + surgery, and 4% steroids. CRS grade (G) 1-2 occurred in 50%, with no G3-4 CRS. ICANS G 1, 2, and 3 occurred in 13%, 21%, and 4%, respectively, with no G 4 ICANS. One pt developed delayed parkinsonism, and another developed leukoencephalopathy; both had CNS MM diagnosed pre-BsAbs and achieved a CNS response (1 complete, 1 partial). Infections occurred in 67% of pts, with 42% being severe, and 1 infection-related death. The systemic ORR of 18 evaluable pts was 67%, including 22% CR, 17% VGPR, and 28% PR. The overall CNS response of 19 evaluable pts was 58%, including 37% complete CNS response and 21% partial CNS response. Of 11 pts achieving a CNS response, 82% didn't have subsequent CNS progression. In 9 pts achieving CNS response after BsAb initiation, the median time to CNS response was 0.9 months (range 0.03-2.8), with an unreached median duration of CNS response. With a median follow-up of 11 months, the median PFS was 5.0 months (95% CI 2.5-NA) and OS was 12.2 months (95% CI 7.7-NA). No significant difference in median PFS (10.6 vs 4.6 months, p=0.11) or OS (20.2 vs 9.3 months, p=0.37) was observed between BCMA BsAbs (n=11) and talquetamab (n=11). Due to small sample limitation, no significant difference was observed in the median PFS (4.6 vs 8.2 months, p=0.48) or OS (20.2 vs 9.9 months, p=0.73) between BsAb monotherapy (n=19) and BsAb combination therapy (n=3). One pt who received teclistamab as a bridge to CAR-T achieved a complete CNS response and remains progression-free to date, demonstrating the best long-term outcome with a PFS of 674 days. Conclusions Our study demonstrates that BsAb use in pts with CNS MM is safe without increased incidence of ICANS. The use of BsAbs in combination with a multimodal CNS-directed approach led to an overall CNS response rate of 58% and an unreached median duration of CNS response. Previous studies (Gaballa et al., 2025) reported a 100% CNS response rate with CAR-T. In this study, 1 pt treated with BsAb as a bridge to CAR-T had the longest PFS, warranting further research to evaluate this combination's efficacy in this very high-risk population.
Milrinone in Advanced Heart Failure: Current Evidence, Clinical Applications, and Future Directions
Castillo‐Rodriguez, Cristian, Juarez, Michel, Cruz, Diego , Thiravetyan, Ben, Puchongmart, Chanokporn , Roman, Sherif , Abdelnabi, Mahmoud , Frishman, William H. , Aronow, Wilbert S.

Mayo Clinic

Cardiology in Review | November 26, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/crd.0000000000001075 | PMID 41296998 Get It

Positive inotropic agents have an important role in the management of acute decompensated heart failure patients with reduced cardiac output and poor end-organ perfusion. However, despite their acute hemodynamic benefits, the role of inotropes in the management of chronic advanced heart failure remains limited to palliative therapy or as a bridging strategy to mechanical support or heart transplantation. Milrinone is one of the most common inotropic agents used in advanced heart failure to provide symptomatic relief and improved hemodynamics. This review discusses the current evidence of milrinone’s efficacy, indications, outcomes in advanced heart failure, evidence gap, and future directions.
First-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3 -associated hypertrophic cardiomyopathy: initial safety, pharmacodynamic, and imaging results from MyPEAK-1
Desai, Milind Y. , Nagueh, Sherif F. , Giudicessi, John R. , Kellner, Danielle, Pollman, Matthew J., Varfaj, Fatbardha, Robertson, Laura, Sonicheva-Paterson, Natasha, Pushkin, Richard, Mangal, Brian, Tomlinson, LaTanya, Harrison, W. G., Yamamoto, Lynn, Argast, Gretchen, Ivey, Kathryn N. , Tingley, Whittemore G., Previs, Michael J. , Sonicheva‐Paterson, Natalia , Harrison, William G, Yamamoto, Lynn, Lombardi, Laura Marie

Mayo Clinic

Cardiovascular Research | November 9, 2025 | Volume: 121 | Issue: 17 | Pages: 2628-2631

10.1093/cvr/cvaf200 | PMID 41206746 Get It

Abstract This brief report details the initial findings from a Phase 1b/2 trial of TN-201, an adeno-associated virus serotype 9 (AAV9) gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), a condition with significant morbidity, increased risk of mortality, and no approved therapy for the majority of patients. TN-201 was well tolerated, and changes to the management of potential immune responses resulted in a shorter period of immunosuppression. These results show consistent transduction and expression of TN-201 in cardiomyocytes, corresponding with increases in MyBP-C levels, reductions or stabilization of cardiac biomarkers, and reductions in key measures of left ventricular (LV) hypertrophy.
Late Gadolinium Enhancement and Electrocardiographic Associations in Hypertrophic Cardiomyopathy
Asfour, Issa, Karim, Shahid , Tabraiz, Sair Ahmad , Chahal, C. Anwar A. , Sherif, Akil Adrian , Ommen, Steve R. , Lin, Grace , Brady, Peter A. , Tabraiz, Sair A, Chahal, Choudhary Anwar A , Sherif, Akil , Khanji, Mohammed Y , Somers, Virend K.

Mayo Clinic

Annals of Noninvasive Electrocardiology | June 12, 2025 | Volume: 30 | Issue: 4 | Pages: No page available

10.1111/anec.70077 | PMID 40464065 Get It

ABSTRACTBackgroundLate gadolinium enhancement (LGE) on cardiovascular magnetic resonance (CMR) imaging is a well‐established indicator of myocardial fibrosis in hypertrophic cardiomyopathy (HCM). However, its association with electrocardiographic (ECG) abnormalities and the risk of atrial fibrillation (AF) remains uncertain.ObjectivesTo investigate the association between the presence and burden of LGE with ECG characteristics, including precordial voltage, depolarization and repolarization abnormalities, and the incidence of AF in adults with HCM.MethodsWe conducted a retrospective cohort study of 144 adults with HCM with CMR and 12‐lead ECG within 30 days of each other. LGE was quantified as a percentage of LV mass and categorized as absent, < 5%, or ≥ 5%. ECG parameters, including QRS voltage, repolarization abnormalities, and LVH criteria, were analyzed. Incident AF was assessed during a median follow‐up of 6.6 years.ResultsLGE was present in 96 (67%) patients, with 21 (22%) having ≥ 5% LGE. There were no significant differences in precordial voltage between patients with and without LGE across Sokolow‐Lyon, Cornell, and Romhilt‐Estes criteria. However, T‐wave inversion was more common in leads I (41% vs. 19%, p = 0.009), aVL (50% vs. 31%, p = 0.033), and V4 (41% vs. 23%, p = 0.035) in patients with LGE. Patients with ≥ 5% LGE had a significantly lower median LVEF (64% vs. 74%, p = 0.003). Additionally, LGE presence was not associated with an increased risk of incident AF (HR 1.8, 95% CI 0.6–5.3, p = 0.308).ConclusionIn contrast to pediatric HCM, LGE is associated with specific ECG repolarization abnormalities, particularly T‐wave inversion in lateral leads, but does not significantly affect precordial voltage in adults.
Efficacy of Total‐Body Irradiation‐based Intensified Myeloablative Regimens for Acute Leukemia—An International Collaborative Study
Arai, Yasuyuki , Brazauskas, Ruta , He, Naya, Al‐Homsi, A. Samer, Yanada, Masamitsu , Steinberg, Amir , Hong, Sanghee , Bashey, Asad, Frangoul, Haydar , Verdonck, Leo F. , Aljurf, Mahmoud , Dias, Ajoy , Wirk, Baldeep , Freytes, César O. , Zeidan, Amer M., Lehmann, Leslie , Rangarajan, Hemalatha G. , Hashmi, Shahrukh K. , Yano, Shingo , Ozawa, Yukiyasu , Doki, Noriko, Kanda, Yoshinobu , Fukuda, Takahiro , Katayama, Yuta, Tanaka, Junji, Okamoto, Shinichiro , Saber, Wael , Yanada, Masamitsu , Kanda, Junya , Badawy, Sherif M , Sharma, Akshay , Abid, Muhammad Bilal , Wirk, Baldeep , Hashmi, Shahrukh, Kanda, Yoshinobu , Ichinohe, Tatsuo , Teshima, Takanori , Okamoto, Shinichiro , Atsuta, Yoshiko , Arai, Yasuyuki , Brazauskas, Ruta , Chhabra, Saurabh , Battiwalla, Minoo , Díaz, Miguel Ángel , Badawy, Sherif M. , Lazarus, Hillard M. , Yared, Jean A. , Hashem, Hasan , Sharma, Akshay , Abid, Muhammad Bilal , Zeidan, Amer M. , Gergis, Usama , Beitinjaneh, Amer , Askar, Medhat , Pu, Jeffrey J , Wood, William A. , Kako, Shinichi , Doki, Noriko , Katayama, Yuta

Mayo Clinic

eJHaem | May 28, 2025 | Volume: 6 | Issue: 3 | Pages: No page available

10.1002/jha2.70061 | PMID 40438703 Get It

ABSTRACTBackgroundIn this study, we compared outcomes of intensified myeloablative conditioning regimens using large registry data from Japan (Japanese Society for Transplantation and Cellular Therapy) and the United States (Center for International Blood and Marrow Transplant Research).MethodsAdult patients who underwent their first myeloablative allogeneic hematopoietic stem cell transplantation (HSCT) for acute leukemia in remission between 2010 and 2018 using conditioning regimens of cyclophosphamide plus total‐body irradiation (CY/TBI), CY/TBI+cytarabine (AraC), or CY/TBI+etoposide (VP16) were included.ResultsThe acute myeloid leukemia (AML) cohort (N = 480, 38.8%) indicated that overall survival (OS) was poorer in CY/TBI+AraC (hazard ratio [HR] 1.46, p < 0.001) and CY/TBI+VP16 (HR 1.39, p = 0.059) compared to CY/TBI. Relapse was not suppressed, while treatment‐related mortality (TRM) was significantly higher (HR 1.78 and 1.74, p < 0.001 and 0.018, respectively). In the acute lymphoblastic leukemia (ALL) cohort (N = 3901, 61.2%), OS was comparable among these regimens. With intensified regimens, relapse was significantly suppressed in CY/TBI+VP16 (HR 0.74, p = 0.005), while TRM was higher (HR 1.21, p = 0.077). No interactions were observed regarding the country.ConclusionIn AML adding AraC and VP16 to CY/TBI had an adverse effect on OS. Conversely, in ALL, adding VP16 or AraC to CY/TBI did not affect survival, but the addition of VP16 reduced the risk of relapse.Clinical Trial RegistrationThe authors have confirmed clinical trial registration is not needed for this submission.
Impact of antithrombotic medications on postprocedural outcomes of percutaneous endoscopic gastrostomy: a US Collaborative Network study
Abusuliman, Mohammed , Elbenawi, Hossam , Abosheaishaa, Hazem , Mohamed, Mouhand , Nassar, Mahmoud , Elhanafi, Sherif , Mohamed, Mouhand F H , Elfert, Khaled , Abosheaishaa, Hazem Maarouf , Beran, Azizullah , Krafft, Matthew

Mayo Clinic

European Journal of Gastroenterology & Hepatology | May 13, 2025 | Volume: 37 | Issue: 9 | Pages: 1021-1025

10.1097/meg.0000000000002990 | PMID 40359274 Get It

Background and aims Percutaneous endoscopic gastrostomy (PEG) is an essential procedure for patients who require long-term enteral nutrition but are unable to eat orally. However, it carries a risk of bleeding, particularly in patients on anticoagulation or dual antiplatelet therapy (DAPT). This study aimed to assess the bleeding risk associated with continuing anticoagulation or DAPT during PEG placement. Methods Using the TriNetX US Collaborative Network Database, we analyzed four cohorts: patients on anticoagulants, patients not on anticoagulants, patients on DAPT, and patients on aspirin (ASP), focusing on gastrostomy-related bleeding within 7 and 30 days, along with secondary outcomes such as mortality and the need for blood transfusion or endoscopic reintervention. Results Our analysis showed no statistically significant difference in the 7-day bleeding risk between the anticoagulant and no anticoagulant groups. However, a higher 30-day bleeding risk was observed in the anticoagulant group (0.9 vs. 0.4%, P = 0.007). There was no significant difference in the incidence of severe bleeding events requiring endoscopic intervention or blood transfusion. In addition, the difference in the bleeding risk between the DAPT and ASP groups was not statistically significant within 7 and 30 days. Conclusion These findings suggest that while anticoagulant use increases the risk of minor post-PEG bleeding, it does not lead to a higher incidence of severe bleeding. Additionally, the continuation of DAPT was not associated with statistically significant increase in bleeding risk. This study provides valuable insights into the management of antithrombotic therapy in patients undergoing PEG.